On September 25, the FDA approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor-positive, human epidermal growth factor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy. For more information, read the FDA announcement and the Eli Lilly and Company press release.
On September 25, the FDA approved imlunestrant, an estrogen receptor antagonist, for adults with estrogen receptor-positive, human epidermal growth factor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
For more information, read the FDA announcement and the Eli Lilly and Company press release.
Posted on 9/26/2025
From challenging misconceptions about breast cancer to incorporating paramedical tattooing for survivors after reconstruction, gather valuable takeaways from Oncology Issues in observance of Breast Cancer Awareness Month.
